Prevention of intestinal toxic effects and intensification of Irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002

Clinical Cancer Research

Volumn 4, Issue 9, 1998, Pages 2053-2063

  Shinohara, Hisashi ^a   Killion, Jerald J ^a   Kuniyasu, Hiroki ^a   Kumar, Rakesh ^a   Fidler, Isaiah J ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRINOTECAN; JBT 3002; LIPOPEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE S PHASE; COLON CANCER; CYTOTOXICITY; DEATH; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; LAMINA PROPRIA; LIVER METASTASIS; MACROPHAGE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR CELL CULTURE; WEIGHT REDUCTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; INTESTINAL DISEASES; LIPOPROTEINS; LIVER NEOPLASMS, EXPERIMENTAL; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED BALB C;

EID: 0031685534     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Gerrits, C. J. H., de Jonge, M. J. A., Schellens, J. H. M., Stoter, G., and Verweij, J. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br. J. Cancer, 76: 952-962, 1997.
2. Rothenberg, M. L., Eckardt, J. R., Kuhn, J. G., Burris, H. A., III, Nelson, J., Hilsenbeck, S. G., Rodriguez, G. I., Thurman, A. M., Smith, L. S., Eckhardt, S. G., Weiss, G. R., Elfring, G. L., Rinaldi, D. A., Schaaf, L. J., and Von Hoff, D. D. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J. Clin. Oncol., 14: 1128-1135, 1996.
3. Shimada, Y., Yoshino, M., Wakui, A., Nakao, I., Futatsuki, K., Sakata, Y., Kambe, M., Taguchi, T., and Ogawa, N. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol., 11: 909-913, 1993.
4. Bleiberg, H., and Cvitkovic, E. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Eur. J. Cancer, 32A (Suppl 3): S18-S23, 1996.
5. Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., Yokokura, T., Sawada, S., Miyasaka, T., and Mutai, M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res., 47: 5944-5947, 1987.
6. Shao, R-G., Cao, C-X., Shimizu, T., O'Connor, P. M., Kohn, K. W., and Pommier, Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res., 57: 4029-4035, 1997.
7. Cascinu, S. Drug therapy in diarrheal diseases in oncology hematology patients. Crit. Rev. Oncol. Hematol., 18: 37-50, 1995.
8. Abigerges, D., Armand, J. P., Chabot, G. G., Da Costa, L., Fadel, E., Cote, C., Horait, P., and Gandia, D. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J. Natl. Cancer Inst., 86: 446-449, 1994.
9. Ikuno, N., Soda, H., Watanabe, M., and Oka, M. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J. Natl. Cancer Inst., 87: 1876-1883, 1995.
10. Podolsky, D. K. Healing the epithelium: solving the problem from two sides. J. Gastoenterol., 32: 122-126, 1997.
11. Reinecker, H. C., MacDermott, R. P., Mirau, S., Dignass, A., and Podolsky, D. K. Intestinal epithelial cells both express and respond to interleukin 15. Gastroenterology, 111: 1706-1713, 1996.
12. Ijiri, K., and Potten, C. S. Response of intestinal cells of differing topographical and hierarchical status to ten cytotoxic drugs and five sources of radiation. Br. J. Cancer, 47: 175-183, 1983.
13. Yamamoto, M., Vancott, J. L., Okahashi, N., Marinaro, M., Kiyono, H., Fujihashi, K., Jackson, R. J., Chatfield, S. N., Bluethmann, H., and McGhee, J. R. The role of Th1 and Th2 cells for mucosal IgA responses. Ann. NY Acad. Sci., 778: 64-71, 1996.
14. Ramsay, A. J., Husband, A. J., Ramshaw, I. A., Bao, S., Matthaei, K. I., Koehler, G., and Kopf, M. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science (Washington DC), 264: 561-563, 1994.
15. Grabstein, K. H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung, V., Beers, C., Richardson, J., Schoenborn, M. A., Ahdieh, M., Johnson, L., Alderson, M. R., Watson, J. D., Anderson, D. M., and Gin, J. G. Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science (Washington DC), 264: 965-968, 1994.
16. Armitage, R. J., Macduff, B. M., Eisenman, J., Paxton, R., and Grabstein, K. H. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J. Immunol., 154: 483-490, 1995.
17. Takeuchi, M., Nishizaki, Y., Sano, O., Ikeda, M., and Kurimoto, M. Immunohistochemical and immunoelectron-microscopic detection of interferon-γ-inducing factor ("interleukin-18") in mouse intestinal epithelial cells. Cell Tissue Res., 289: 499-503, 1997.
18. Utsugi, T., Nii, A., Fan, D., Pak, C. C., Denkins, Y., van Hoogevest, P., and Fidler, I. J. Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages. Cancer Imunol. Imunother., 33: 285-292, 1991.
19. Killion, J. J., Bucana, C. D., Radinsky, R., Dong, Z., O'Reilly, T., Bilbe, G., Tarcsay L., and Fidler, I. J. Maintenance of intestinal epithelium structural integrity and mucosal leukocytes during chemotherapy by oral administration of muramyl tripeptide phosphatidylethanolamine. Cancer Biother. Radiopharm., 11: 363-371, 1996.
20. Saiki, I., and Fidler, I. J. Synergistic activation by recombinant mouse interferon-γ and muramyl dipeptide of tumoricidal properties in mouse macrophages. J. Immunol., 135: 684-688, 1985.
21. Saiki, I., Milas, L., Hunter, N., and Fidler, I. J. Treatment of experimental lung metastasis with local thoracic irradiation followed by systemic macrophage activation with liposomes containing muramyl tripeptide. Cancer Res., 46: 4966-4970, 1986.
22. Killion, J. J., and Fidler, I. J. Systemic targeting of liposome-encapsulated immunomodulators to macrophages for treatment of cancer metastasis. Immunomethods, 4: 273-279, 1994.
23. Eue, I., Kumar, R., Dong, Z., Killion, J. J., and Fidler, I. J. Improved activation of nitric oxide production and tumoricidal properties in murine macrophages by a novel synthetic lipopeptide JT3002 encapsulated in liposomes. J. Immunother., in press, 1998.
24. Kumar, R., Eue, I, Dong, Z., Killion, J. J., and Fidler, I. J. Expression of inflammatory cytokines by murine macrophages activated with a new synthetic lipopeptide JBT 3002. Cancer Biother. Radiopharm., 12: 333-340, 1997.
25. Dong, Z., Radinsky, R., Fan, D., Tsan, R., Bucana, C. D., Wilmanns, C., and Fidler, I. J. Organ-specific modulation of steady-state mdr-1 gene expression and drug resistance in murine colon cancer cells. J. Natl. Cancer Inst., 86: 913-920, 1994.
26. Fujimaki, T., Ellis, L. M., Bucana, C. D., Radinsky, R., Price, J. E., and Fidler, I. J. Simultaneous radiolabel, genetic tagging, and proliferation assays to study the organ distribution and fate of metastatic cells. Int. J. Oncol., 2: 895-901, 1993.
27. Takahashi, Y., Bucana, C. D., Liu, W., Yoneda, J., Kitadai, Y., Cleary, K. R., and Ellis, L. M. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J. Natl. Cancer Inst., 88: 1146-1151, 1996.
28. Xie, K., Wang, Y., Huang, S., Xu, L., Bielenberg, D., Salas, T., McConkey, D., Jiang, W., and Fidler, I. J. Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with downregulation of Bcl-2. Oncogene, 15: 771-779, 1997.
29. Dong, Z., Qi, X., and Fidler, I. J. Tyrosine phosphorylation of mitogen-activated protein kinase is necessary for activation of murine macrophages by natural and synthetic bacterial products. J. Exp. Med., 177: 1071-1077, 1993.
30. Quaroni, A., Calnek, D., Quaroni, E., and Chandler, J. S. Keratin expression in rat intestinal crypt and villus cells. J. Biol. Chem., 266: 11923-11931, 1991.
31. Araki, E., Ishikawa, M., Iigo, M., Koide, T., Itabashi, M., and Hoshi, A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res., 84: 697-702, 1993.
32. Farrell, C. L., Bready, J. V., Rex, K. L., Chen, J. N., DiPalma, C. R., Whitcom, K. L., Yin, S., Hill, D. C., Wiemann, B., Starnew, C. O., Havil, A. M., Lu, Z-N., Aukerman, S. L., Pierce, G. F., Thomason, A., Potten, C. S., Ulich, T. R., and Lacey, D. L. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res., 58: 933-939, 1998.
33. Doherty, T. M., Seder, R. A., and Sher, A. Induction and regulation of IL-15 expression in murine macrophages. J. Immunol., 156: 735-741, 1996.
34. Dignass, A., Lynch-Devaney, K., Kindon, H., Thim, L., and Podolsky, D. K. Trefoil peptides promote epithelial migration through a transforming growth factor β-independent pathway. J. Clin. Invest., 94: 376-383, 1994.
35. Talmadge, J. E., Key, M. E., and Fidler, I. J. Macrophage content of metastatic and nonmetastatic rodent neoplasms. J. Immunol., 126: 2245-2248, 1981.
36. Fidler, I. J., Fogler, W. E., Brownbill, A. F., and Schumann, G. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide. J. Immunol., 138: 4509-4514, 1987.
37. Fidler, I. J. Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Immunol. Immunother., 21: 169-173, 1986.
38. Poste, G., Bucana, C. D., Raz, A., Bugelski, P., Kirsh, R., and Fidler, I. J. Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res., 42: 1412-1422, 1982.
39. Chabner, B. A., and Meyers, C. E. Clinical pharmacology of cancer chemotherapy. In: V. T. deVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, 3rd ed., pp. 349-395. Philadelphia: J. B. Lippincott, 1989.
40. Wang, Z., and Sinha, B. K. Interleukin-1α-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo. Mol. Pharmacol., 49: 269-275, 1996.
41. Kaneda, N., Nagata, H., Furuta, T., and Yokokura, T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res., 50: 1715-1720, 1990.
42. Araki, E., Ishikawa, M., Iigo, M., Koide, T., Itabashi, M., and Hoshi, A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res., 84: 697-702, 1993.